Alicia Okines
A5065638223- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Breast Cancer Treatment Studies
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Lung Cancer Research Studies
- Gastrointestinal Tumor Research and Treatment
- COVID-19 and healthcare impacts
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 and COVID-19 Research
- Chronic Lymphocytic Leukemia Research
- Chromatin Remodeling and Cancer
- Mechanisms of cancer metastasis
- Pancreatic and Hepatic Oncology Research
- Breast Lesions and Carcinomas
- Peptidase Inhibition and Analysis
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
Royal Marsden Hospital
2016-2025
Royal Marsden NHS Foundation Trust
2016-2025
Institute of Cancer Research
2016-2024
Breast Cancer Now
2023
National Health Service
2020
Medical Research Council
2016
University College London
2016
Institute of Cancer Research
2016
University of Leeds
2016
University of Padua
2016
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy multiple HER2-targeted agents limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. We randomly assigned patients HER2-positive previously treated trastuzumab, pertuzumab, and trastuzumab emtansine, had or did not brain metastases, to receive either tucatinib placebo, in combination...
Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI) are prognostic for survival in many cancers resistance to fluoropyrimidines early colon cancer. However, the effect of MMRD MSI curatively resected gastric cancer treated with perioperative chemotherapy is unknown.
In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) tucatinib. We describe exploratory analyses of intracranial efficacy and participants BMs.Patients were randomly assigned 2:1 to tucatinib or placebo, combination trastuzumab capecitabine. All underwent baseline magnetic resonance imaging; those BMs classified as active stable....
BackgroundPeri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, monoclonal antibody against VEGF, improves the proportion responding to treatment in advanced gastric cancer. We aimed assess safety efficacy adding bevacizumab peri-operative gastric, junction, or lower oesophageal adenocarcinoma.MethodsIn this multicentre, randomised, open-label phase 2–3 trial, we recruited aged 18 years older histologically...
Purpose The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification at risk relapse remains challenging. We evaluated whether pathologic response lymph node status after neoadjuvant are prognostic in treated the MAGIC trial. Materials Methods Pathologic regression was assessed resection...
BackgroundNeoadjuvant chemotherapy before surgery improves survival compared with alone for patients oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant further improved current standard regimen.MethodsOE05 was an open-label, phase 3, randomised clinical trial. Patients surgically resectable adenocarcinoma classified as stage cT1N1, cT2N1, cT3N0/N1, or cT4N0/N1 were recruited from 72 UK hospitals. Eligibility criteria included WHO...
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is prospective cohort study of COVID-19 immunity patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable titers neutralizing antibodies (NAbT) against severe acute...
In the primary analysis of HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) progression-free (PFS) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. We report efficacy safety outcomes, including final OS outcomes from follow-up HER2CLIMB.HER2CLIMB is a randomized, double-blind, placebo-controlled trial locally advanced or HER2+ cancer, brain metastases. Patients were randomized : 1...
Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer (TNBC) patients predicts high risk relapse. c-TRAK TN assessed the utility prospective ctDNA surveillance TNBC and activity pembrolizumab with detected [ctDNA positive (ctDNA+)].c-TRAK TN, a multicentre phase II trial, integrated by digital PCR, enrolled residual disease following neoadjuvant chemotherapy, or stage II/III adjuvant chemotherapy. comprised three-monthly blood sampling to 12...
To evaluate the efficacy and safety of tucatinib trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) metastatic biliary tract cancer (mBTC).
Complete resection of metastases can result in cure for selected patients with metastatic colorectal cancer. First BEAT evaluated the safety bevacizumab first-line chemotherapy 1914 patients. Prospectively collected data from 225 who underwent curative-intent surgery were analysed, including an exploratory comparison rate treated different regimens. NO16966 compared efficacy oxaliplatin-based plus or placebo 1400 A retrospective analysis was undertaken. In BEAT, out (11.8%) at median 64 days...
Purpose Epirubicin, oxaliplatin, and capecitabine (EOC) is a standard treatment in advanced esophagogastric cancer. Panitumumab (P) fully human, immunoglobulin G2 monoclonal antibody targeting epidermal growth factor receptor. Randomized Trial of EOC ± for Advanced Locally Esophagogastric Cancer (REAL-3) will evaluate whether the addition P to improves survival patients with adenocarcinoma undifferentiated carcinoma. Patients Methods The original design REAL-3 added 9 mg/kg dose (dose level...
Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast evolves with time and under selective pressure treatment, potential acquire mutations resistance treatment disease progression. To identify potentially targetable in advanced cancer, we performed prospective characterization a cohort patients ABC.Biopsies from were sequenced 41 genes targeted panel ABC Biopsy (ABC-Bio) study. Blood samples collected at progression for...
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2 positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies 82% neutralizing against wild type SARS-CoV-2, whereas antibody titers Alpha, Beta Delta variants substantially reduced. levels decreased in 13% patients, remained stable for up to...
Advances in treatment, common cardiovascular (CV) risk factors and the ageing of population have led to an increasing number cancer patients presenting with acute CV diseases. These events may be related itself or treatment. Acute cardiac care specialists must aware these complications able manage them. This require individualized multidisciplinary approach. We summarize most cytotoxic, targeted, immune-based therapies. is followed by a proposal for approach where cardiologists work close...
Abstract Background Tucatinib is a highly selective HER2-directed tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for previously treated HER2+ locally advanced or metastatic breast cancer (LA/MBC). Trastuzumab emtansine (T-DM1) antibody-drug conjugate to treat LA/MBC taxane. This the first report of HER2CLIMB-02 (NCT03975647), randomized, double-blind, placebo-controlled phase 3 study assessing efficacy safety tucatinib combined T-DM1 patients LA/MBC....
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell and differentiation, is overexpressed in several tumor types, including breast, gastric colorectal cancer. HER2-targeted therapies have shown clinical activity against these resulting regulatory approvals. However, the efficacy of HER2 tumors with mutations has not been widely investigated. SGNTUC-019 an open-label, phase basket study evaluating tucatinib, a tyrosine kinase inhibitor, combination...